Notably, in prostate cancer cells, reducing the expression of BTK-C by RNAi or inhibiting its activity using BTK-specific inhibitors such as ibrutinib, AVL-292, or CGI-1746 leads to a decrease in cell survival. This evidence concerns the gene BTK and prostate carcinoma.